ITF Therapeutics LLC
Mary Jane Salinas, PharmD, currently serves as the Head of US Scientific Communications and Evidence Generation at ITF Therapeutics LLC since July 2024. Previously, Mary Jane held the position of Director, Head of Publications at Intercept Pharmaceuticals from September 2022 to July 2024 and served as the Head of Scientific Communications at Taysha Gene Therapies between June 2021 and October 2022. Prior roles include Associate Director, US Medical Communications at EMD Serono, Inc., and Manager of Medical Information at Teva Pharmaceuticals. Mary Jane has extensive experience in medical communications strategy, publication planning, and scientific communications across various therapeutic areas, including neurology and rare diseases. A Doctor of Pharmacy, Mary Jane earned the degree from the University of Missouri-Kansas City.
This person is not in the org chart
This person is not in any teams
ITF Therapeutics LLC
ITF Therapeutics is the U.S.-based rare disease division of Italfarmaco S.p.A. Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development of many innovative therapeutic products approved for use by patients around the world. The company operates in more than 60 countries on five continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas. In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases including Duchenne muscular dystrophy (DMD). Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the U.S. patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics also reflects Italfarmaco’s goal to build a world-class team of experts that share a passion to make a positive impact for rare disease communities.